Viral Vector Manufacturing

As the gene therapy industry continues to grow and more adeno-associated virus (AAV)–based gene therapies achieve regulatory approval, establishing a seamless path-to-market is becoming increasingly important. One challenge that manufacturers are currently facing during this process is the transition from research and development to clinical trials and commercialization—specifically, balancing the need to scale up production volumes while maintaining consistent quality.

Central to achieving efficient workflow scale-up are scalable and consistent components. This is because the scalability of the cell culture media and transfection reagents used can have a major impact on process performance.

Additionally, as you move to commercial manufacturing, it is more important than ever for workflow components to be consistent in terms of both quality and supply. By offering innovative Gibco products and dedicated support services backed by a robust global manufacturing network, Thermo Fisher Scientific can help you scale up your AAV manufacturing workflow with confidence and meet your project goals.

Gene therapy is proving to be a powerful potential treatment option, leading to increasingly high demand. Although timelines are being compressed, it is critical for manufacturers to think about the sustainability and future of their upstream processes. By considering the long-term feasibility of their workflows in the earlier stages of development, manufacturers have a greater chance of maintaining productivity and preventing later process changes, which can be costly and time-consuming.

For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.